RLMD Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of --. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Oragenics, Inc.'s return on equity of -509.23%.

Relmada Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 37.5%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Relmada Therapeutics, Inc..

Relmada Therapeutics, Inc. has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of 16.24%. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Relmada Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 37.5%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -33.84%. Given that Relmada Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Relmada Therapeutics, Inc. has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 1.25x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of --. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Palatin Technologies's return on equity of --.

Relmada Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 37.5%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Relmada Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Relmada Therapeutics, Inc..

Relmada Therapeutics, Inc. has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Relmada Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Relmada Therapeutics, Inc.'s net income of -$10.1M is higher than Palatin Technologies's net income of --. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Relmada Therapeutics, Inc.'s net margin of --. Relmada Therapeutics, Inc.'s return on equity of -214.4% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Relmada Therapeutics, Inc. has a consensus price target of $1.00, signalling upside risk potential of 37.5%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Relmada Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Relmada Therapeutics, Inc..

Relmada Therapeutics, Inc. has a beta of 0.740, which suggesting that the stock is 25.972% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Relmada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relmada Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Relmada Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Relmada Therapeutics, Inc.'s net income of -$10.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Relmada Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relmada Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.